Barclays downgraded Definitive Healthcare (DH) to Underweight from Equal Weight with an unchanged price target of $4. Definitive has declining revenue in fiscal 2025, which is not characteristic of the software group, driven by increased churn with life sciences customers that has not improved, the analyst tells investors in a research note. The firm says the company’s changes to its sales force are being made to rectify declining customer count and weaker renewals, but notes the changes take time to implement and will likely take down margins.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH: